Balyasny Asset Management
LYEL icon

Balyasny Asset Management’s Lyell Immunopharma LYEL Stock Holding History

Balyasny Asset Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-59,879
Closed -$1.65M – 3042
2024
Q3 		$1.65M Buy
59,879
+10,612
+22% +$312K ﹤0.01% 1751
2024
Q2 		$1.43M Buy
49,267
+37,429
+316% +$1.78M ﹤0.01% 1653
2024
Q1 		$528K Buy
+11,838
New +$507K ﹤0.01% 2026
2022
Q4 		– Sell
-1,675
Closed -$245K – 3034
2022
Q3 		$245K Buy
+1,675
New +$227K ﹤0.01% 2259
2022
Q2 		– Sell
-3,388
Closed -$342K – 2986
2022
Q1 		$342K Buy
+3,388
New +$410K ﹤0.01% 1897
2021
Q4 		– Sell
-6,427
Closed -$1.9M – 2461
2021
Q3 		$1.9M Buy
+6,427
New +$1.93M 0.01% 1158

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return